| Joel David Duff, MD | |
|
425 Highway 51 N, Brookhaven, MS 39601-2350 | |
| (601) 833-5713 | |
| (601) 748-7063 |
| Full Name | Joel David Duff |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 9 Years |
| Location | 425 Highway 51 N, Brookhaven, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386038651 | NPI | - | NPPES |
| 14935523 | Other | MS | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 1G0841 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| King's Daughters Medical Center-brookhaven | Brookhaven, MS | Hospital |
| St Dominic-jackson Memorial Hospital | Jackson, MS | Hospital |
| Southwest Ms Regional Medical Center | Mccomb, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brookhaven Urology, Pa | 9638227804 | 2 |
News Archive
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
The natural molecule, n-acetylcysteine (NAC), with strong antioxidant effects, shows potential benefit as part of the management for patients with Parkinson's disease, according to a study published today in the journal PLOS ONE.
UK trainee doctors working in emergency care claim they are gaining less experience of common practical procedures, suggests a small study in Emergency Medicine Journal.
› Verified 2 days ago
| Entity Name | Brookhaven Urology, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154421006 PECOS PAC ID: 9638227804 Enrollment ID: O20090427000446 |
News Archive
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
The natural molecule, n-acetylcysteine (NAC), with strong antioxidant effects, shows potential benefit as part of the management for patients with Parkinson's disease, according to a study published today in the journal PLOS ONE.
UK trainee doctors working in emergency care claim they are gaining less experience of common practical procedures, suggests a small study in Emergency Medicine Journal.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joel David Duff, MD 425 Highway 51 N, Brookhaven, MS 39601-2350 Ph: (601) 833-5713 | Joel David Duff, MD 425 Highway 51 N, Brookhaven, MS 39601-2350 Ph: (601) 833-5713 |
News Archive
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.
ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.
The natural molecule, n-acetylcysteine (NAC), with strong antioxidant effects, shows potential benefit as part of the management for patients with Parkinson's disease, according to a study published today in the journal PLOS ONE.
UK trainee doctors working in emergency care claim they are gaining less experience of common practical procedures, suggests a small study in Emergency Medicine Journal.
› Verified 2 days ago
Dr. Jeffrey G Clark, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 425 Highway 51 N, Brookhaven, MS 39601 Phone: 601-833-5713 Fax: 601-833-1616 | |
Dr. James Jeffery Boyd, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 425 Highway 51 N, Brookhaven, MS 39601 Phone: 601-833-5713 Fax: 601-833-1616 |